Cue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Business Officer
09 sept. 2024 08h00 HE
|
Cue Biopharma, Inc.
BOSTON, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and...
Cue Biopharma to Present at The Promise of Interleukin-2 Therapy Conference
03 sept. 2024 08h00 HE
|
Cue Biopharma, Inc.
BOSTON, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and...
Cue Biopharma Reports Second Quarter 2024 Financial Results and Recent Business Highlights
19 août 2024 16h05 HE
|
Cue Biopharma, Inc.
BOSTON, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and...
Cue Biopharma to Host Business Update Call and Webcast
13 août 2024 08h00 HE
|
Cue Biopharma, Inc.
BOSTON, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and...
Cue Biopharma Announces Strategic Prioritization of Autoimmune Programs Enabling Optimization of Workforce and Reduction of Capital Requirements
25 juil. 2024 16h05 HE
|
Cue Biopharma, Inc.
Prioritizing autoimmune programs aims to focus upon near-term and intermediate value creation potential, while retaining oncology programs as promising clinical data continues to mature - Company...
Cue Biopharma Presents Updated Data from Phase 1 Trial of CUE-101 in Recurrent/Metastatic HPV+ Head and Neck Cancer at the 2024 ASCO Annual Meeting
04 juin 2024 08h00 HE
|
Cue Biopharma, Inc.
Overall response rate (ORR) of 46% and 12-month overall survival (OS) of 96% in first line (1L) recurrent/metastatic (R/M) HPV+ head and neck squamous cell carcinoma (HNSCC) treated with CUE-101 and...
Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences in June 2024
03 juin 2024 08h00 HE
|
Cue Biopharma, Inc.
BOSTON, June 03, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and...
Cue Biopharma Reports First Quarter 2024 Financial Results and Recent Business Highlights
09 mai 2024 16h05 HE
|
Cue Biopharma, Inc.
BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and...
Cue Biopharma to Present at the 20th Annual PEGS Boston Summit
08 mai 2024 08h00 HE
|
Cue Biopharma, Inc.
BOSTON, May 08, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate...
Cue Biopharma to Participate in Fireside Chat at The Citizens JMP Life Sciences Conference
07 mai 2024 08h00 HE
|
Cue Biopharma, Inc.
BOSTON, May 07, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate...